GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Net Interest Income

Evolus (FRA:EVL) Net Interest Income : €-14.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Evolus's net interest income for the three months ended in Dec. 2024 was €-3.6 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2024 was €-14.3 Mil.

Evolus Net Interest Income Historical Data

The historical data trend for Evolus's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Net Interest Income Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.11 -1.24 -8.48 -11.90 -14.78

Evolus Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.47 -3.85 -3.41 -3.46 -3.61

Evolus Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Net Interest Income Related Terms

Thank you for viewing the detailed overview of Evolus's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Net Interest Income
Comparable Companies
AVDL PAHC TLRY HROW COLL ORGO NIKA AKBA ELTP BGM ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
EOLS:USA 0K16:UK
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Website
https://www.evolus.com
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines